FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 329:1-7 July 1, 1993 Number 1 Next

	Full Text Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Although digoxin is effective in the treatment of patients with chronic heart failure who are receiving diuretic agents, it is not clear whether the drug has a role when patients are receiving angiotensin-converting-enzyme inhibitors, as is often the case in current practice.

Methods We studied 178 patients with New York Heart Association class II or III heart failure and left ventricular ejection fractions of 35 percent or less in normal sinus rhythm who were clinically stable while receiving digoxin, diuretics, and an angiotensin-converting-enzyme inhibitor (captopril or enalapril). The patients were randomly assigned in a double-blind fashion either to continue receiving digoxin (85 patients) or to be switched to placebo (93 patients) for 12 weeks. Otherwise, their medical therapy for heart failure was not changed.

Results Worsening heart failure necessitating withdrawal from the study developed in 23 patients switched to placebo, but in only 4 patients who continued to receive digoxin (P<0.001). The relative risk of worsening heart failure in the placebo group as compared with the digoxin group was 5.9 (95 percent confidence interval, 2.1 to 17.2). All measures of functional capacity deteriorated in the patients receiving placebo as compared with those continuing to receive digoxin (P = 0.033 for maximal exercise tolerance, P = 0.01 for submaximal exercise endurance, and P = 0.019 for New York Heart Association class). In addition, the patients switched from digoxin to placebo had lower quality-of-life scores (P = 0.04), decreased ejection fractions (P = 0.001), and increases in heart rate (P = 0.001) and body weight (P<0.001).

Conclusions These findings indicate that the withdrawal of digoxin carries considerable risks for patients with chronic heart failure and impaired systolic function who have remained clinically stable while receiving digoxin and angiotensin-converting-enzyme inhibitors.

Source Information

From the Mount Sinai School of Medicine, New York (M.P.); Henry Ford Hospital, Detroit (M.G.); Baylor College of Medicine, Houston (J.B.Y.); the University of Medicine and Dentistry of New Jersey, Camden (P.J.C.); the University of North Carolina, Chapel Hill (K.F.A.); Ohio State University School of Medicine, Columbus (R.J.C.); the Arizona Heart Institute, Tucson (L.K.S.); the Washington Hospital Center, Washington, D.(L.V.V.); G.H. Besselaar Associates, Princeton, N.J. (L.A.G.); and Burroughs Wellcome Co., Research Triangle Park, N.(M.K.J.).

Address reprint requests to Dr. Packer at the Division of Circulatory Physiology and Center for Heart Failure Research, Columbia University, College of Physicians and Surgeons, 630 W. 168th St., New York, NY 10032.

Full Text of this Article

Related Letters:

Withdrawal of Digoxin from Patients with Chronic Heart Failure Treated with Angiotensin-Converting-Enzyme Inhibitors
O'Mara N. B., Zimmerman W. B., Joffe I., Devereux R. B., Packer M., Gheorghiade M., Young J. B.
Extract | Full Text  
N Engl J Med 1993; 329:1819-1820, Dec 9, 1993. Correspondence

This article has been cited by other articles:

• Coca, S. G., Krumholz, H. M., Garg, A. X., Parikh, C. R. (2006). Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease.. JAMA 296: 1377-1384 [Abstract] [Full Text]  
• Gheorghiade, M., Sopko, G., De Luca, L., Velazquez, E. J., Parker, J. D., Binkley, P. F., Sadowski, Z., Golba, K. S., Prior, D. L., Rouleau, J. L., Bonow, R. O. (2006). Navigating the Crossroads of Coronary Artery Disease and Heart Failure. Circulation 114: 1202-1213 [Full Text]  
• Gheorghiade, M., van Veldhuisen, D. J., Colucci, W. S. (2006). Contemporary Use of Digoxin in the Management of Cardiovascular Disorders. Circulation 113: 2556-2564 [Full Text]  
• Ahmed, A., Rich, M. W., Love, T. E., Lloyd-Jones, D. M., Aban, I. B., Colucci, W. S., Adams, K. F., Gheorghiade, M. (2006). Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J 27: 178-186 [Abstract] [Full Text]  
• Young, J. B. (2005). Whither Withering's Legacy?: Digoxin's Role in Our Contemporary Pharmacopeia for Heart Failure. J Am Coll Cardiol 46: 505-507 [Full Text]  
• Ioannidis, J. P. A. (2005). Contradicted and Initially Stronger Effects in Highly Cited Clinical Research. JAMA 294: 218-228 [Abstract] [Full Text]  
• Olsson, L. G., Swedberg, K., Clark, A. L., Witte, K. K., Cleland, J. G.F. (2005). Six minute corridor walk test as an outcome measure for the assessment of treatment in randomized, blinded intervention trials of chronic heart failure: a systematic review. Eur Heart J 26: 778-793 [Abstract] [Full Text]  
• Burger, P. C., Rocca, H. B.-L. (2005). Pharmacotherapy of Congestive Heart Failure in Elderly Patients. J CARDIOVASC PHARMACOL THER 10: 85-94 [Abstract]  
• Yan, A. T., Yan, R. T., Liu, P. P. (2005). Narrative Review: Pharmacotherapy for Chronic Heart Failure: Evidence from Recent Clinical Trials. ANN INTERN MED 142: 132-145 [Abstract] [Full Text]  
• Cayley, W. E Jr (2004). Digoxin in chronic heart failure. Fam Pract 21: 469-472 [Full Text]  
• Rahimtoola, S. H. (2004). Digitalis Therapy for Patients in Clinical Heart Failure. Circulation 109: 2942-2946 [Full Text]  
• Gheorghiade, M., Adams, K. F. Jr, Colucci, W. S. (2004). Digoxin in the Management of Cardiovascular Disorders. Circulation 109: 2959-2964 [Full Text]  
• Dorn, G. W. II, Molkentin, J. D. (2004). Manipulating Cardiac Contractility in Heart Failure: Data From Mice and Men. Circulation 109: 150-158 [Full Text]  
• Khand, A. U., Rankin, A. C., Martin, W., Taylor, J., Gemmell, I., Cleland, J. G. F. (2003). Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure?. J Am Coll Cardiol 42: 1944-1951 [Abstract] [Full Text]  
• McKenzie, D B, Cowley, A J (2003). Drug therapy in chronic heart failure. Postgrad. Med. J. 79: 634-642 [Abstract] [Full Text]  
• Salukhe, T. V., Henein, M. Y., Sutton, R. (2003). Pacing in heart failure: patient and pacing mode selection. Eur Heart J 24: 977-986 [Full Text]  
• Kjeldsen, K, Norgaard, A, Gheorghiade, M (2002). Myocardial Na,K-ATPase: the molecular basis for the hemodynamic effect of digoxin therapy in congestive heart failure. Cardiovasc Res 55: 710-713 [Abstract] [Full Text]  
• Abraham, W. T., Fisher, W. G., Smith, A. L., Delurgio, D. B., Leon, A. R., Loh, E., Kocovic, D. Z., Packer, M., Clavell, A. L., Hayes, D. L., Ellestad, M., Trupp, R. J., Underwood, J., Pickering, F., Truex, C., McAtee, P., Messenger, J., the MIRACLE Study Group, (2002). Cardiac Resynchronization in Chronic Heart Failure. NEJM 346: 1845-1853 [Abstract] [Full Text]  
• Adams, K. F. Jr, Gheorghiade, M., Uretsky, B. F., Patterson, J. H., Schwartz, T. A., Young, J. B. (2002). Clinical benefits of low serum digoxin concentrations in heart failure. J Am Coll Cardiol 39: 946-953 [Abstract] [Full Text]  
• van Veldhuisen, D. J. (2002). Low-dose digoxin in patients with heart failure: Less toxic and at least as effective?. J Am Coll Cardiol 39: 954-956 [Full Text]  
• Ahmed, A., Allman, R. M., DeLong, J. F. (2002). Inappropriate Use of Digoxin in Older Hospitalized Heart Failure Patients. J. Gerontol. A Biol. Sci. Med. Sci. 57: M138-143 [Abstract] [Full Text]  
• Petrie, M.C., Berry, C., Stewart, S., McMurray, J.J.V. (2001). Failing ageing hearts. Eur Heart J 22: 1978-1990  
• Cleland, J. G F, John, J., Dhawan, J., Clark, A. (2001). What is the optimal medical management of ischaemic heart failure?. Br Med Bull 59: 135-158 [Abstract] [Full Text]  
• Rich, M. W., McSherry, F., Williford, W. O., Yusuf, S., for the Digitalis Investigation Group, (2001). Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: the DIG study. J Am Coll Cardiol 38: 806-813 [Abstract] [Full Text]  
• Opasich, C, Pinna, G.D, Mazza, A, Febo, O, Riccardi, R, Riccardi, P.G, Capomolla, S, Forni, G, Cobelli, F, Tavazzi, L (2001). Six-minute walking performance in patients with moderate-to-severe heart failure; is it a useful indicator in clinical practice?. Eur Heart J 22: 488-496 [Abstract]  
• Stevenson, L. W., Kormos, R. L. (2001). Mechanical cardiac support 2000: current applications and future trial design: June 15-16, 2000 Bethesda, Maryland. J Am Coll Cardiol 37: 340-370 [Full Text]  
• Geraci, J. M., Knowlton, A. A. (2000). Spironolactone for Heart Failure : Spiraling Out of Control. Chest 118: 1522-1523 [Full Text]  
• Lonn, E., McKelvie, R. (2000). Regular review: Drug treatment in heart failure. BMJ 320: 1188-1192 [Full Text]  
• Krumholz, H. M., Baker, D. W., Ashton, C. M., Dunbar, S. B., Friesinger, G. C., Havranek, E. P., Hlatky, M. A., Konstam, M., Ordin, D. L., Pina, I. L., Pitt, B., Spertus, J. A. (2000). Evaluating Quality of Care for Patients With Heart Failure. Circulation 101 : e122-e140 [Full Text]  
• Rich, M. W., Nease, R. F. (1999). Cost-effectiveness Analysis in Clinical Practice: The Case of Heart Failure. Arch Intern Med 159: 1690-1700 [Abstract] [Full Text]  
• Guyatt, G. (1999). A 75-Year-Old Man With Congestive Heart Failure. JAMA 281: 2321-2328 [Full Text]  
• Petrie, M. C., Dawson, N. F., Murdoch, D. R., Davie, A. P., McMurray, J. J. V. (1999). Failure of Women's Hearts. Circulation 99: 2334-2341 [Full Text]  
• Hauptman, P. J., Kelly, R. A. (1999). Digitalis. Circulation 99: 1265-1270 [Abstract] [Full Text]  
• Elovaara, I., Lalla, M., Spare, E., Lehtimaki, T., Dastidar, P. (1998). Methylprednisolone reduces adhesion molecules in blood and cerebrospinal fluid in patients with MS. Neurology 51: 1703-1708 [Abstract] [Full Text]  
• Williamson, K. M., Thrasher, K. A., Fulton, K. B., LaPointe, N. M. A., Dunham, G. D., Cooper, A. A., Barrett, P. S., Patterson, J. H. (1998). Digoxin Toxicity: An Evaluation in Current Clinical Practice. Arch Intern Med 158: 2444-2449 [Abstract] [Full Text]  
• Dalakas, M. C. (1998). Mechanism of Action of Intravenous Immunoglobulin and Therapeutic Considerations in the Treatment of Autoimmune Neurologic Diseases. Neurology 51: S2-S8 [Abstract] [Full Text]  
• Dalakas, M. C. (1998). Controlled Studies with High-Dose Intravenous Immunoglobulin in the Treatment of Dermatomyositis, Inclusion Body Myositis, and Polymyositis. Neurology 51: S37-S45 [Abstract] [Full Text]  
• Morrell, M. J. (1998). Guidelines for the care of women with epilepsy. Neurology 51: S21-S27 [Abstract] [Full Text]  
• O'Keeffe, S T, Lye, M, Donnellan, C, Carmichael, D N (1998). Reproducibility and responsiveness of quality of life assessment and six minute walk test in elderly heart failure patients. Heart 80: 377-382 [Abstract] [Full Text]  
• Zahn, C. A., Morrell, M. J., Collins, S. D., Labiner, D. M., Yerby, M. S. (1998). Management issues for women with epilepsy: A review of the literature. Neurology 51: 949-956 [Abstract] [Full Text]  
• Sellebjerg, F., Frederiksen, J. L., Nielsen, P. M., Olesen, J. (1998). Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS. Neurology 51: 529-534 [Abstract] [Full Text]  
• Shuhaiber, S., Pastuszak, A., Schick, B., Matsui, D., Spivey, G., Brochu, J., Koren, G. (1998). Pregnancy outcome following first trimester exposure to sumatriptan. Neurology 51: 581-583 [Abstract] [Full Text]  
• Ogawa, N. (1998). Early introduction of dopamine agonists in the long-term treatment of Parkinson's disease. Neurology 51: S13-S20 [Abstract] [Full Text]  
• Silver, D. E., Ruggieri, S. (1998). Initiating therapy for Parkinson's disease. Neurology 50: S18-S22 [Abstract] [Full Text]  
• Waters, C. H., Kurth, M., Bailey, P., Shulman, L. M., LeWitt, P., Dorflinger, E., Deptula, D., Pedder, S., Tolcapone Stable Study Group, (1998). Tolcapone in stable Parkinson's disease: Efficacy and safety of long-term treatment. Neurology 50: S39-S45 [Abstract] [Full Text]  
• Soderstrom, M., Ya-Ping, J., Hillert, J., Link, H. (1998). Optic neuritis: Prognosis for multiple sclerosis from MRI, CSF, and HLA findings. Neurology 50: 708-714 [Abstract] [Full Text]  
• (1998). Management of Parkinson's disease. Neurology 50: S2-S57 [Full Text]  
• Schmidt, T. A, Kjeldsen, K. (1998). Human myocardial Na,K-ATPase -- quantification, regulation and relation to Ca. Cardiovasc Res 37: 335-345 [Full Text]  
• Gheorghiade, M., Bonow, R. O. (1998). Chronic Heart Failure in the United States : A Manifestation of Coronary Artery Disease. Circulation 97: 282-289 [Full Text]  
• Pablos-Mendez, A., Barr, R. G., Shea, S. (1998). Run-in Periods in Randomized Trials: Implications for the Application of Results in Clinical Practice. JAMA 279: 222-225 [Abstract] [Full Text]  
• Sullebarger, J. T., D'Ambra, P. M., Clark, L. C., Thanikarry, L., Fontanet, H. L. (1998). Effect of Digoxin on Ventricular Remodeling and Responsiveness of {beta}-Adrenoceptors in Chronic Volume Overload. J CARDIOVASC PHARMACOL THER 3: 281-290 [Abstract]  
• Sanderson, J E, Chan, S K W, Yu, C M, Yeung, L Y C, Chan, W M, Raymond, K, Chan, K W, Woo, K S (1998). beta Blockers in heart failure: a comparison of a vasodilating beta  blocker with metoprolol. Heart 79: 86-92 [Abstract] [Full Text]  
• Lockwood, A. H., Salvi, R. J., Coad, M. L., Towsley, M. L., Wack, D. S., Murphy, B. W. (1998). The functional neuroanatomy of tinnitus: Evidence for limbic system links and neural plasticity. Neurology 50: 114-120 [Abstract] [Full Text]  
• Droogan, A. G., Crockard, A. D., McMillan, S. A., Hawkins, S. A. (1998). Effects of intravenous methylprednisolone therapy on leukocyte and soluble adhesion molecule expression in MS. Neurology 50: 224-229 [Abstract] [Full Text]  
• Kapoor, R., Miller, D. H., Jones, S. J., Plant, G. T., Brusa, A., Gass, A., Hawkins, C. P., Page, R., Wood, N. W., Compston, D. A. S., Moseley, I. F., McDonald, W. I. (1998). Effects of intravenous methylprednisolone on outcome in MRI-based prognostic subgroups in acute optic neuritis. Neurology 50: 230-237 [Abstract] [Full Text]  
• Resnick, S. M., Metter, E. J., Zonderman, A. B. (1997). Estrogen replacement therapy and longitudinal decline in visual memory: A possible protective effect?. Neurology 49: 1491-1497 [Abstract] [Full Text]  
• Optic Neuritis Study Group*, (1997). The 5-year risk of MS after optic neuritis: Experience of the Optic Neuritis Treatment Trial. Neurology 49: 1404-1413 [Abstract] [Full Text]  
• Matsumori, A., Ono, K., Nishio, R., Igata, H., Pharm, B, Shioi, T., Matsui, S., Furukawa, Y., Iwasaki, A., Nose, Y., Sasayama, S. (1997). Modulation of Cytokine Production and Protection Against Lethal Endotoxemia by the Cardiac Glycoside Ouabain. Circulation 96: 1501-1506 [Abstract] [Full Text]  
• Peroutka, S. J. (1997). Dopamine and migraine. Neurology 49: 650-656 [Abstract] [Full Text]  
• Waters, C. H., Kurth, M., Bailey, P., Shulman, L. M., LeWitt, P., Dorflinger, E., Deptula, D., Pedder, S., the Tolcapone Stable Study Group, (1997). Tolcapone in stable Parkinson's disease: Efficacy and safety of long-term treatment. Neurology 49: 665-671 [Abstract] [Full Text]  
• Geerlings, M. I., Deeg, D.J. H., Schmand, B., Lindeboom, J., Jonker, C. (1997). Increased risk of mortality in Alzheimer's disease patients with higher education? A replication study. Neurology 49: 798-802 [Abstract] [Full Text]  
• Adler, C. H., Sethi, K. D., Hauser, R. A., Davis, T. L., Hammerstad, J. P., Bertoni, J., Taylor, R. L., Sanchez-Ramos, J., O'Brien, C. F., Ropinirole Study Group, (1997). Ropinirole for the treatment of early Parkinson's disease. Neurology 49: 393-399 [Abstract] [Full Text]  
• Umans, V. A., Cornel, J. H., Hic, C., Soto, J., Avendano, C., Vilchez, F. G., Bohm, M., Zoneraich, S., Yusuf, S., Gorlin, R., Garg, R., Packer, M. (1997). Digoxin in Patients with Heart Failure. NEJM 337: 129-131 [Full Text]  
• Peroutka, S. J., Wilhoit, T., Jones, K. (1997). Clinical susceptibility to migraine with aura is modified by dopamine D2 receptor (DRD2) Nco I alleles. Neurology 49: 201-206 [Abstract] [Full Text]  
• Stern, M. B. (1997). Contemporary approaches to the pharmacotherapeutic management of Parkinson's disease: An overview. Neurology 49: S2-S9 [Abstract] [Full Text]  
• Watts, R. L. (1997). The role of dopamine agonists in early Parkinson's disease. Neurology 49: S34-S48 [Abstract] [Full Text]  
• Waters, C. H. (1997). Managing the late complications of Parkinson's disease. Neurology 49: S49-S57 [Abstract] [Full Text]  
• Tulloch, I. F. (1997). Pharmacologic profile of ropinirole: A nonergoline dopamine agonist. Neurology 49: S58-S62 [Abstract] [Full Text]  
• Schechter, N. L., Blankson, V., Pachter, L. M., Sullivan, C. M., Costa, L. (1997). The Ouchless Place: No Pain, Children's Gain. Pediatrics 99: 890-890 [Full Text]  
• Willmore, L. J. (1997). Care of adults with epilepsy in the United States. Neurology 48: S39-S43 [Full Text]  
• Barohn, R. J. (1997). The therapeutic dilemma of inclusion body myositis. Neurology 48: 567-568 [Full Text]  
• Dalakas, M. C., Sonies, B., Dambrosia, J., Sekul, E., Cupler, E., Sivakumar, K. (1997). Treatment of inclusion-body myositis with IVIg: A double-blind, placebo-controlled study. Neurology 48: 712-716 [Abstract] [Full Text]  
• Dowson, A. J. (1997). 311C90: Patient profiles and typical case histories of migraine management. Neurology 48: 29S-33S [Abstract] [Full Text]  
• The Digitalis Investigation Group, (1997). The Effect of Digoxin on Mortality and Morbidity in Patients with Heart Failure. NEJM 336: 525-533 [Abstract] [Full Text]  
• Packer, M. (1997). End of the Oldest Controversy in Medicine -- Are We Ready to Conclude the Debate on Digitalis?. NEJM 336: 575-576 [Full Text]  
• Ogunyankin, K., Singh, B. N. (1997). Reflections on Recent Clinical Trials in Patients With Heart Failure and Those With Reduced Ventricular Function. J CARDIOVASC PHARMACOL THER 2: 147-152  
• Amato, A. A., McVey, A., Cha, C., Matthews, E. C., Jackson, C. E., Kleingunther, R., Worley, L., Cornman, E., Kagan-Hallet, K. (1997). Evaluation of Neuromuscular Symptoms in Veterans of the Persian Gulf War. Neurology 48: 4-12 [Abstract] [Full Text]  
• Hamalainen, M. L., Hoppu, K., Valkeila, E., Santavuori, P. (1997). Ibuprofen or Acetaminophen for the Acute Treatment of Migraine in Children: A Double-blind, Randomized, Placebo-controlled, Crossover Study. Neurology 48: 103-107 [Abstract] [Full Text]  
• Litvan, I., Agid, Y., Goetz, C., Jankovic, J., Wenning, G. K., Brandel, J. P., Lai, E. C., Verny, M., Ray-Chaudhuri, K., McKee, A., Jellinger, K., Pearce, R.K.B., Bartko, J. J. (1997). Accuracy of the Clinical Diagnosis of Corticobasal Degeneration: A Clinicopathologic Study. Neurology 48: 119-125 [Abstract] [Full Text]  
• Hasenfuss, G., Mulieri, L. A., Allen, P. D., Just, H., Alpert, N.R. (1996). Influence of Isoproterenol and Ouabain on Excitation-Contraction Coupling, Cross-Bridge Function, and Energetics in Failing Human Myocardium. Circulation 94: 3155-3160 [Abstract] [Full Text]  
• Scelsa, S. N., Simpson, D. M., McQuistion, H. L., Fineman, A., Ault, K., Reichler, B. (1996). Clozapine-induced myotoxicity in patients with chronic psychotic disorders. Neurology 47: 1518-1523 [Abstract] [Full Text]  
• Packer, M., Colucci, W. S., Sackner-Bernstein, J. D., Liang, C.-s., Goldscher, D. A., Freeman, I., Kukin, M. L., Kinhal, V., Udelson, J. E., Klapholz, M., Gottlieb, S. S., Pearle, D., Cody, R. J., Gregory, J. J., Kantrowitz, N. E., LeJemtel, T. H., Young, S. T., Lukas, M. A., Shusterman, N. H. (1996). Double-Blind, Placebo-Controlled Study of the Effects of Carvedilol in Patients With Moderate to Severe Heart Failure: The PRECISE Trial. Circulation 94: 2793-2799 [Abstract] [Full Text]  
• , (1996). INFORMATION IN PRACTICE. BMJ 313: 1062-1062 [Full Text]  
• Brannagan, T. H. III, Nagle, K. J., Lange, D. J., Rowland, L. P. (1996). Complications of intravenous immune globulin treatment in neurologic disease. Neurology 47: 674-677 [Abstract] [Full Text]  
• Bain, P. G., Motomura, M., Newsom-Davis, J., Misbah, S. A., Chapel, H. M., Lee, M. L., Vincent, A., Lang, B. (1996). Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology 47: 678-683 [Abstract] [Full Text]  
• Grand, S., Lai, E. S., Esteve, F., Rubin, Ch., Hoffmann, D., Remy, C., Segebarth, Ch. (1996). In vivo sup 1 H MRS of brain abscesses versus necrotic brain tumors. Neurology 47: 846-848 [Full Text]  
• Cohn, J. N. (1996). The Management of Chronic Heart Failure. NEJM 335: 490-498 [Full Text]  
• Litvan, I., Agid, Y., Calne, D., Campbell, G., Dubois, B., Duvoisin, R. C., Goetz, C. G., Golbe, L. I., Grafman, J., Growdon, J. H., Hallett, M., Jankovic, J., Quinn, N. P., Tolosa, E., Zee, D. S. (1996). Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): Report of the NINDS-SPSP International Workshop. Neurology 47: 1-9 [Abstract] [Full Text]  
• Massie, B. M., Fisher, S. G., Deedwania, P. C., Singh, B. N., Fletcher, R. D., Singh, S. N. (1996). Effect of Amiodarone on Clinical Status and Left Ventricular Function in Patients With Congestive Heart Failure. Circulation 93: 2128-2134 [Abstract] [Full Text]  
• Pfeffer, M. A., Stevenson, L. W. (1996). {beta}-Adrenergic Blockers and Survival in Heart Failure. NEJM 334: 1396-1397 [Full Text]  
• Nolte, K. B., Brass, L. M., Fletterick, C. F. (1996). Intracranial hemorrhage associated with cocaine abuse: A prospective autopsy study. Neurology 46: 1291-1291 [Abstract] [Full Text]  
• Ringel, S. P. (1996). Future neurology workforce: The right kind and number of neurologists. Neurology 46: 897-900 [Full Text]  
• Litvan, I., Agid, Y., Jankovic, J., Goetz, C., Brandel, J. P., Lai, E. C., Wenning, G., D'Olhaberriague, L., Verny, M., Chaudhuri, K. R., McKee, A., Jellinger, K., Bartko, J. J., Mangone, C. A., Pearce, R.K.B. (1996). Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Neurology 46: 922-930 [Abstract] [Full Text]  
• Newman, N. J. (1996). Optic neuropathy. Neurology 46: 315-322 [Full Text]  
• Rolak, L. A., Beck, R. W., Paty, D. W., Tourtellotte, W. W., Whitaker, J. N., Rudick, R. A., for the Optic Neuritis Study Group, (1996). Cerebrospinal fluid in acute optic neuritis: Experience of the optic neuritis treatment trial. Neurology 46: 368-372 [Abstract] [Full Text]  
• Lublin, F. D., Whitaker, J. N., Eidelman, B. H., Miller, A. E., Arnason, B.G.W., Burks, J. S. (1996). Management of patients receiving interferon beta-1b for multiple sclerosis: Report of a consensus conference. Neurology 46: 12-18 [Abstract] [Full Text]  
• Porter, J. D., Baker, R. S. (1996). Muscles of a different 'color': The unusual properties of the extraocular muscles may predispose or protect them in neurogenic and myogenic disease. Neurology 46: 30-37 [Full Text]  
• Asanoi, H., Kameyama, T., Ishizaka, S., Nozawa, T., Inoue, H. (1996). Energetically Optimal Left Ventricular Pressure for the Failing Human Heart. Circulation 93: 67-73 [Abstract] [Full Text]  
• Koller, W. C., Silver, D., Lieberman, A. (1995). Reply from the Supplement Editors: Supplement: Treatment for Parkinson's disease. Neurology 45: 2301-2302 [Full Text]